Literature DB >> 12045056

Changes in ultrasound findings in posterior uveal melanoma after Ruthenium 106 brachytherapy.

Igor Kaiserman1, Irene Anteby, Itay Chowers, Eytan Z Blumenthal, Iris Kliers, Jacob Pe'er.   

Abstract

PURPOSE: To analyze the postbrachytherapy ultrasonographic dynamics of uveal melanoma tumor height and internal reflectivity.
DESIGN: Prospective, comparative, observational case series. PARTICIPANTS: One hundred forty-seven patients (147 eyes) with posterior uveal melanoma having a mean age of 61 years (range, 29-97 years) who were treated with Ruthenium 106 brachytherapy.
METHODS: Patients were followed-up with ultrasonography using both A and B modes of standardized echography every 6.7 +/- 0.3 months (mean +/- standard error of the mean) for a total of 1001 ultrasound examinations. On average, each patient was examined 5.8 times (range, 3-17 times). The echographic parameters included tumor base size, height, internal reflectivity, regularity, vascularity, and extra-scleral extension. To compare the response of tumors of different sizes, each tumor was standardized to its initial size at brachytherapy. MAIN OUTCOME MEASURES: The dynamics of the tumor height and internal reflectivity.
RESULTS: At the time of brachytherapy, the mean height of the tumors was 5.2 mm (range, 2.2-11.8 mm). After brachytherapy, 142 tumors (96.6%) responded by a decrease in height. The decrease in height was at an initial rate of approximately 3% per month. Most of the tumors did not regress entirely; rather, their height stabilized on a constant value (on average 61% of the initial height) after approximately 18 to 24 months. The decrease in height after brachytherapy was best fitted by the sum of a first order exponential decay and a constant (h = 61 + 35*e(-0.12t), in which t = time in months). The half-life of the decay was 5.8 months. Large tumors (>8 mm) had a faster initial decrease in height, and stabilized on a lower percentage of their initial height (50%) compared with small tumors (70%). Thus, the half-life of the height exponential decay was 5.3 months for small tumors (2-4 mm) and 3.3 months for the large tumors (>8 mm). Internal reflectivity increased from a mean of 40% before therapy to 70% after 2 years. The dynamics of the reflectivity were best fitted with the function: f = 45 + 24(1-e(-0.09t)). Larger tumors, which initially had lower internal reflectivity, presented with a slower increase in internal reflectivity (t() = 8.7 months) compared with smaller tumors (t(1/2) = 5 months).
CONCLUSIONS: The postbrachytherapy ultrasonographic dynamics of uveal melanomas resemble a function composed of the sum of a constant and a first order exponent, suggesting the possible existence of two components (cell populations), one unaffected by brachytherapy and the other a radiosensitive population that reacts to brachytherapy in an exponential decay. An exponential decay can imply that the postbrachytherapy death of each tumor cell is a stochastic Markovian process that is independent of the death of other tumor cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12045056     DOI: 10.1016/s0161-6420(02)01054-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  13 in total

1.  Ruthenium-106 plaque radiotherapy alone or in combination with transpupillary thermotherapy in the management of choroidal melanoma.

Authors:  Kaan Gündüz; Rengin Aslihan Kurt; Hale Elif Akmeşe; Kenan Köse; Omür Uçakhan-Gündüz
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

2.  Uveal melanoma: molecular pattern, clinical features, and radiation response.

Authors:  Michael C Chappell; Devron H Char; Tia B Cole; J William Harbour; Kavita Mishra; Vivian K Weinberg; Theodore L Phillips
Journal:  Am J Ophthalmol       Date:  2012-04-27       Impact factor: 5.258

3.  [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].

Authors:  L M Heindl; M Lotter; V Strnad; R Sauer; G O H Naumann; H L J Knorr
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

4.  Diffusion-weighted magnetic resonance imaging and ultrasound evaluation of choroidal melanomas after proton-beam therapy.

Authors:  Andrea Russo; Cesare Mariotti; Antonio Longo; Pietro Valerio Foti; Teresio Avitabile; Maurizio Giacinto Uva; Livio Marco Franco; Vincenza Bonfiglio; Pietro Milone; Giovanni Carlo Ettorre; Marco Ragusa; Michele Purrello; Rosario Caltabiano; Lidia Puzzo; Michele Reibaldi
Journal:  Radiol Med       Date:  2015-02-04       Impact factor: 3.469

5.  Uveal Melanoma Regression after Brachytherapy: Relationship with Chromosome 3 Monosomy Status.

Authors:  Sachin M Salvi; Hassan A Aziz; Suhail Dar; Nakul Singh; Brandy Hayden-Loreck; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2016-10-29

6.  Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma.

Authors:  I Kaiserman; I Anteby; I Chowers; E Z Blumenthal; I Kliers; J Pe'er
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

7.  Regression patterns of choroidal melanoma: After palladium-103 (103Pd) plaque brachytherapy.

Authors:  Abhilasha Maheshwari; Paul T Finger
Journal:  Eur J Ophthalmol       Date:  2018-05-22       Impact factor: 2.597

8.  Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I.

Authors:  David Miguel; Jesús María de Frutos-Baraja; Francisco López-Lara; María Antonia Saornil; Ciro García-Álvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2018-08-31

9.  Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy.

Authors:  Rui Fang; Heng Wang; Yang Li; Yue-Ming Liu; Wen-Bin Wei
Journal:  BMC Ophthalmol       Date:  2021-03-16       Impact factor: 2.209

10.  Ultrasound Biomicroscopy Documented Anterior Uveal Melanoma Regression after Ruthenium-106 Plaque Therapy.

Authors:  Biljana Kuzmanović Elabjer; Mladen Bušić; Andrej Pleše; Mirjana Bjeloš; Daliborka Miletić; Nenad Vukojević
Journal:  Ocul Oncol Pathol       Date:  2021-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.